Taylor & Francis Group
Browse

Infographic – Summary of the CaboPoint study

Download (2.18 MB)
figure
posted on 2021-12-20, 14:30 authored by Laurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, David Perol, Viktor Grünwald, Eric Guemas
CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma

Funding

Ipsen

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    cabozantinibcheckpoint inhibitorrenal cell carcinomasecond linetyrosine kinase inhibitorCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC